Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

Table 1 Patient characteristics

	Study						Overall N = 934
	CECOG GET vs FEC N = 256		AGO Mamma 1 N = 514		AGO Mamma 3 N = 164
Age, years
median (range)	53.5 (29-74)		56.0 (28-75)		58.0 (21-76)		56.0 (21-76)
	N	%	N	%	N	%	N	%
HR status
ER and/or PgR positive	118	67.43	324	69.83	131	80.37	573	71.45
missing	81		50		1		132
Her2
positive	-	-	-	-	30	23.08	30	23.08
missing	256		514		34		804
Nodal status at first diagnosis
positive	164	65.08	282	65.58	95	67.86	541	65.82
missing	4		84		24		112
ECOG PS
0	122	47.66	237	46.11	104	65.00	463	49.78
1 or 2	134	52.34	277	53.89	56	35.00	467	50.22
missing	0		0		4		4
Prior chemotherapy
none	126	49.22	325	63.98	96	58.54	547	58.94
non-anthracycline	130	50.78	162	31.89	34	20.73	326	35.13
anthracycline	0	0	21	4.13	34	20.73	55	5.93
missing	0		6		0		6
Prior endocrine therapy
yes	99	38.67	220	44.62	85	51.83	404	44.25
missing	0		21		0		21
Metastatic site
high-risk*	207	80.86	318	64.50	113	68.90	638	69.88
missing	0		21		0		21

ISSN: 1471-2407